Therapy Switching in Patients Receiving Long-Acting Opioids

Annals of Pharmacotherapy

Volumn 38, Issue 3, 2004, Pages 389-395

  Berger, Ariel ^a   Hoffman, Deborah L ^b,c   Goodman, Seth ^a,d   Delea, Thomas E ^a   Seifeldin, Raafat ^b   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b PURDUE PHARMA L P   (United States)

^c PharMetrics Inc ^*

^d PharMetrics Inc   (United States)

Author keywords

Healthcare costs; Opiod analgesics; Pharmacotherapy

Indexed keywords

FENTANYL; LONG ACTING DRUG; MORPHINE SULFATE; OPIATE; OXYCODONE;

ADULT; AGED; ARTICLE; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DATA BASE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; THERAPY SWITCHING; TREATMENT PLANNING;

ADMINISTRATION, CUTANEOUS; AGED; ANALGESICS, OPIOID; COMORBIDITY; DELAYED-ACTION PREPARATIONS; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; OXYCODONE; PAIN;

EID: 1242338980     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D109     Document Type: Article

References (21)

1. Parrott T. Using opioid analgesics to manage chronic noncancer pain in primary care. J Am Board Fam Pract 1999;12:293-306.
2. Pappagallo M. Aggressive pharmacologic treatment of pain. Rheum Dis Clin North Am 1999;25:193-213.
3. The use of opioids for the treatment of chronic pain: a consensus statement from American Academy of Pain Medicine and American Pain Society. www.ampainsoc.org/advocacy/opioids.htm (accessed 2002 Apr 2).
4. Jacox A, Carr DB, Payne R. New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med 1994;330:651-5.
5. American Pain Society. Guideline for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. Glenview, PA: American Pain Society, 2002:54-92.
6. Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 1998;2:239-49.
7. Allan L, Hays H, Jensen NH, Le Polain de Waroux B, Bolt M, Donald R, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1-7.
8. Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 2000;14:111-9.
9. Breitbart W, Chandler S, Eagel B, Ellison N, Enck RE, Lefkowitz M, et al. An alternative algorithm for dosing transdermal fentanyl. Oncology 2000;14:695-705.
10. Donner B, Zenz M. Transdermal fentanyl: a new step on the therapeutic ladder. Anticancer Drugs 1995;6:39-43.
11. Johanson GA. New routes of opiate administration. Am J Hosp Palliat Care 1992;9:4-5.
12. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Sympt Manage 1998;15:168-75.
13. Korte W, de Stoutz N, Morant R. Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. J Pain Sympt Manage 1996;11:139-46.
14. Robards M. Transdermal fentanyl in the hospice: a survey of rescue dosing and pain control. Am J Hosp Palliat Care 2001;18:47-50.
15. Professional ICD-9-CM code book. 6th ed. Reston, VA: St. Anthony Publishing, 2000.
16. Current procedural technology. 4th ed. Chicago: American Medical Association, 2000.
17. Allison PD. Survival analysis using the SAS system: a practical guide. Cary, NC: SAS Institute, 1995:29-60, 111-84.
18. Ghali WA, Quan H, Brant R, van Melle G, Norris CM, Faris PD, et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001;286:1494-7.
19. SAS/STAT user's guide, version 8, 4th ed. Volumes 1 & 2. Cary, NC: SAS Institute, 1992.
20. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998;12:533-7.
21. Hensley PL, Nurnberg HG. Formulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfalls. Pharmacoeconomics 2001;19:973-82.